Elixir Medical Corporation’s Post

The Food and Drug Administration (FDA) in the US has approved Boston Scientific Corporation's, FARAPULSE™ Pulsed Field Ablation (PFA) system. ◾The FARAPULSE PFA System is a novel and distinctive substitute for the standard-of-care thermal ablation treatment for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF). ◾Mechanism :- FARAPULSE PFA System uses tissue-selective, non-thermal electric fields to ablate heart tissue without endangering other structures. ◾The device uses FARAWAVE catheter, an over-the-wire device that can be adjusted to fit the specific anatomy of each patient. It is used to treat a variety of pulmonary vein anatomies. ◾The FARAPULSE PFA System was granted Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. FDA in 2019 and received CE Mark in 2021. Boston Scientific plans to immediately launch the system in the US. Source: https://lnkd.in/dsutmxM2 #bostonscientific #medicaldevices #news #whatsnew #cardiology

#medicaldevices #interventionalradiology #cme This one is a bit different, a discussion about complications related to 'glue' / Cyanoacrylate when used in venous interventional procedures: https://lnkd.in/dxZmT-v2 (899 Serious Adverse Events Including 13 Deaths, 7 Strokes, 211 Thromboembolic Events, and 482 Immune Reactions: The Untold Story of Cyanoacrylate Adhesive Closure) The paper I think is this one: https://lnkd.in/dnCSv68i

CIRT-FR is the first CIRSE-sponsored study mandated to support the French ministry of health (HAS) in evaluating the decision of reimbursement renewal of SIR-Spheres yttrium-90 (Y90) resin microspheres in France. Data on the real-life clinical practice of TARE Y90 using SIR-Spheres in patients with primary and secondary liver tumours, as well as safety, effectiveness, and quality of life data, were collected. Learn more about CIRT-FR 👉 https://lnkd.in/d3rkwJp9  Check out our latest publication👉 https://lnkd.in/dbfXrYQN Stay tuned for the two upcoming publications on final results and sub-cohort analysis! #NextResearch #CIRSE #Clinical #Research #ResearchInFocus #IR #SIRT #TARE #InterventionalRadiology

Explore the effects of high-dose atorvastatin pretreatment in STEMI patients undergoing primary PCI, highlighted through a cardiac magnetic resonance study by Kim EK, Hahn J, Song Y, et al. Catch the whole pearl on our website. #PharmacyPearls #Statins #Atorvastatin #PrimaryPCI

Axiostat leverages its proprietary Protonated Bioadhesive Technology (PBT®) to achieve faster haemostasis regardless of the severity of bleeding. The essence of PBT® lies in 4 key mechanisms. Unique charge-based interaction: Accelerates the adherence and aggregation of blood cells and plasma absorption. Platelet activation via Toll-like receptors (TLR) - Crucial for effective haemostasis. Clotting cascade activation (Factor X) – Leading to quick thrombin generation. Fibrin plug formation - Expedites stable clot formation at the bleeding site. In contrast to conventional haemostats, Axiostat activates platelets through TLR receptors, a key feature especially beneficial for patients under anticoagulation therapy. Explore our findings in the Harvard study: https://lnkd.in/d_qEkgb5 For inquiries, visit info.axiobio.com. #Axiostat #bleedingmanagement #anticoagulation #Harvardstudy #medicalresearch #hemostasis #fibrinplug #healthcareinnovation

Join Conformal and Industry leaders at #CRT2024 this weekend for cutting-edge insights and advances in the Cardiovascular industry. On Saturday 9, at 5:00 PM: Explore the future with William Gray, MD., as he presents Conformal Self-Adaptable LAA Closure Device: Initial Clinical Experience." Take this chance to be at the forefront of innovative cardiovascular solutions. Then, on Sunday 10, at 3:24 PM, Dive deep into comparative thrombogenicity with William Gray, MD., as he presents "Comparative Acute Thrombogenicity Of The CLAAS Foam Implant And Watchman FLX In An In Vitro Blood Loop Model." Finally, on Tuesday, 13, at 10:39 AM, Aaron Kaplan, MD, will discuss "Conformal: Design and Clinical Data on a Novel LAA Closure Device." Gain insights into a revolutionary LAA closure device's meticulous design and clinical outcomes. See you there!  To learn more about the CONFORM Pivotal Trial and the CLAAS System, visit https://lnkd.in/exyWTx-x    #Cardiology #LAAO #data #conformalmedical #claas #Afib #CRT2024 #CardioTech #InnovationInTheHeartOfDC #ConformalMedica #interventionalcardiology   CAUTION: Investigational Device The CLAAS System is limited by Federal (or United States) law to investigational use.

The LANDMARK trial published in the Lancet and presented at EuroPCR is cementing the establishment of Meril Myval THV among the leaders of the TAVR market 🤗 The LANDMARK trial compared the new-generation Myval transcatheter heart valve (THV) to contemporary THVs (Sapien and Evolut) in treating severe symptomatic aortic stenosis. Conducted across 31 hospitals in 16 countries, 768 participants, mostly low risk, were randomly assigned to receive either the Myval THV or a contemporary THV (Edwards Lifesciences Sapien series and Medtronic Evolut series). The primary endpoint at 30 days, including a composite of mortality, stroke, bleeding, kidney injury, vascular complications, valve regurgitation, and pacemaker implantation, showed non-inferiority for Myval (25%) compared to contemporary THVs (27%). Regarding stroke risk, the trial observed no significant difference in stroke rates: at 3% for both groups. The similarity in stroke outcomes aligns with the overall finding that Myval's novel sizing does not compromise procedural safety or efficacy. https://lnkd.in/e-PdqGD5 #meril #myval #tavr #landmark #europcr #stroke #prevention #cerebralprotection #bostonscientific #medtronic #edwardslifesciences

We are thrilled to share two-year late-breaking clinical results demonstrating a statistically significant benefit with DynamX® Coronary Bioadaptor System over standard-of-care Resolute OnyxTM Drug-Eluting Stent: ·     65% reduction in target lesion failure (TLF) rate ·     68% reduction in target vessel failure (TVF) rate ·     78% reduction in TLF rate in left anterior descending (LAD) artery lesions Learn more about the BIOADAPTOR Randomized Controlled Trial (RCT) results: https://lnkd.in/ecWk4dse CE marked. Not for sale in the U.S. #EuroPCR #Bioadaptor #Medtech #Innovation #Cardiology

𝗘𝗹𝗲𝘃𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗶𝘁𝗵 𝗙𝗟𝗘𝗫𝗰𝘆𝘁𝗲 𝟵𝟲 - 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗹𝗲 𝗙𝗼𝗿𝗰𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 🚀 Unlock the full potential of hiPSC-derived Cardiomyocytes for disease modeling and in vitro drug screens using the innovative FLEXcyte 96 system. Our cutting-edge technology enables 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗹𝗲 𝗳𝗼𝗿𝗰𝗲 𝗺𝗲𝗮𝘀𝘂𝗿𝗲𝗺𝗲𝗻𝘁, a crucial analysis parameter that significantly enhances the evaluation of drug candidates in cardiac safety, toxicity, and efficacy studies. Key Features: ▪️ 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀: The FLEXcyte 96 plate supports mature cell behavior by providing physiological mechanical conditions. ▪️ 𝗤𝘂𝗮𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗹𝗲 𝗙𝗼𝗿𝗰𝗲 (𝗺𝗡/𝗺𝗺²): The FLEXcyte 96 software suite allows precise measurement of contractile force, a critical factor for assessing cardiac function. Embrace the future of cardiac analytics with FLEXcyte 96. Discover more in the flyer: https://ow.ly/oyH750Rxf7S #FLEXcyte96 #ContractileForce #CardiacResearch #iPSC #Cardiomyocytes #CellAnalytics

📢 The B3 study is the largest and most representative study on CLS in SND patients so far. 📢 #CLS is the only atrial pacing rate modulation algorithm that has proven a significant reduction of subclinical AF incidence in a large, randomized trial. The unique 16% risk reduction of the primary endpoint [AHRE, Stroke, TIA] suggests that CLS provides a more physiologic rate-adaptive pacing than conventional heart rate adaptation in SND patients. The positive effect of CLS on AHRE incidence (HR 0.84) was most beneficial to the SND patient subgroups without AV block (HR 0.77), without history of AF (HR 0.73), or with ventricular pacing <20% (HR 0.78). Let's have a look on the below slider to get to know more about the benefits shown on the #B3Study! #ClosedLoopStimulation #BIOTRONIK #Excelenceforlife